What is the appropriate protocol for converting a patient on sublingual buprenorphine/naloxone (Suboxone) to a transdermal buprenorphine (Butrans) patch, including the required wash‑out period and initial patch strength based on the current Suboxone dose?

Converting Suboxone to Butrans Patch

Based on expert consensus, clinicians may consider switching from sublingual buprenorphine/naloxone (Suboxone) to transdermal buprenorphine (Butrans) for chronic pain management, though this conversion is supported only by very low-quality evidence and requires careful dose consideration due to significant bioavailability differences between formulations. 1

Key Pharmacologic Considerations

The transdermal buprenorphine patch bypasses the 90% first-pass hepatic metabolism that occurs with sublingual formulations, potentially providing better analgesia relative to tablets or films 1. However, this creates a critical dosing challenge: the bioavailability differences mean direct dose conversions are not straightforward.

Conversion Protocol

Important Caveats Before Converting

• Indication matters critically: The Butrans patch is FDA-approved only for chronic pain, NOT for opioid use disorder (OUD) 1. If your patient is on Suboxone for OUD maintenance, this conversion is generally inappropriate unless chronic pain is the primary indication.

• Dose limitations: Butrans patches have a maximum dose of 20 mcg/hour, which delivers significantly less buprenorphine systemically than typical OUD maintenance doses (8-24 mg sublingual daily) 2.

Step-by-Step Conversion Approach

For patients on LOW-DOSE Suboxone (≤8 mg/day) for chronic pain:

1. No washout period is required - you can transition directly from sublingual to transdermal formulation
2. Starting patch strength: Begin with Butrans 5 mcg/hour patch (the lowest dose for opioid-experienced patients) 2
3. Application: Apply patch on the day after the last Suboxone dose
4. Titration: Increase by 5-10 mcg/hour increments every 7 days based on pain control, up to maximum 20 mcg/hour

For patients on HIGHER-DOSE Suboxone (>8 mg/day):

This conversion is problematic and generally not recommended because:

• The maximum Butrans dose (20 mcg/hour) delivers substantially less buprenorphine than 12-16 mg sublingual daily
• Risk of inadequate pain control or withdrawal symptoms is high
• Alternative approach: Consider divided dosing of sublingual buprenorphine (every 6-8 hours) instead of switching to transdermal 1

If Conversion Must Proceed Despite High Dose

1. Taper Suboxone first: Reduce to ≤8 mg/day over 1-2 weeks before attempting conversion
2. Monitor closely: Watch for withdrawal symptoms (restlessness, anxiety, muscle aches, insomnia)
3. Have rescue medication available: Keep short-acting opioids or additional sublingual buprenorphine available for breakthrough pain or withdrawal
4. Frequent follow-up: See patient within 3-5 days of conversion, then weekly for first month

Critical Pitfalls to Avoid

• Don't assume dose equivalence: 8 mg sublingual ≠ any specific transdermal dose due to different pharmacokinetics
• Don't convert patients on Suboxone for OUD: This risks destabilizing their addiction treatment 1
• Don't use Butrans for OUD maintenance: This is off-label and inappropriate 1
• Don't forget naloxone withdrawal: Patients may experience mild withdrawal from stopping naloxone component, though this is typically minimal

Monitoring After Conversion

• Pain scores: Daily for first week, then weekly
• Withdrawal symptoms: Clinical Opiate Withdrawal Scale (COWS) if available
• Respiratory status: Especially in first 72 hours (though buprenorphine has ceiling effect for respiratory depression) 2
• Patch adherence: Ensure proper application technique and 7-day change schedule

When Conversion Fails

If inadequate analgesia persists despite maximum Butrans dose (20 mcg/hour):

1. Return to sublingual buprenorphine in divided doses (every 6-8 hours) 1
2. Add adjuvant analgesics: NSAIDs, acetaminophen, gabapentinoids, topical agents 1
3. Consider adding full agonist opioid: Fentanyl, morphine, or hydromorphone may be needed, though higher doses required due to buprenorphine's receptor binding 1
4. Last resort: Transition to methadone maintenance if all other strategies fail 1

The evidence supporting this conversion is weak (very low quality), and clinical experience is limited 1. The transdermal formulation may offer advantages in tolerability and steady-state delivery, but the dose limitations make it unsuitable for many patients currently maintained on standard Suboxone doses for OUD.